IP Library Granted Patent US 12,280,028
Granted Patent B2
US 12,280,028 · App. 17/216,157 · Granted Apr 22, 2025

Methods and compositions to inhibit dependence on opioids

Inventors: Jacqueline M. Iversen (Lloyd Harbor, NY); Thomas A. Dahl (Guilford, CT)
Assignee: SEN-JAM PHARMACEUTICAL INC.
A61K31/192A61K9/0056A61K9/0058A61P25/36A61K31/4535A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,028
App. No.
17/216,157
Granted
Apr 22, 2025
Kind
B2
Abstract

The present invention provides a method of inhibiting dependence to an opioid by a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject during opioid therapy. The pharmaceutical composition comprises a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof.

Claims (21)

1. A method of inhibiting dependence to an opioid by a human subject in need thereof, comprising:

administering an effective amount of a pharmaceutical composition to the subject during opioid therapy,

wherein the pharmaceutical composition comprises:

a) a non-steroidal anti-inflammatory drug (NSAID); and

b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine, cetirizine, salts thereof and combinations thereof;

wherein dependence to an opioid is inhibited in the human subject.

2. The method of claim 1 wherein the NSAID is selected from the group consisting of: aspirin, ibuprofen, naproxen, diclofenac, diflunisal, etodolac, indomethacin, ketoprofen, ketorolac, meloxicam, nabumetone, oxaprozin, piroxicam, salsalate, sulindac, and tolmetin.

3. The method of claim 1 wherein the NSAID is ibuprofen and the co-agent is fexofenadine.

4. The method of claim 3 wherein the amount of ibuprofen is about 150 mg to about 900 mg, and the amount of fexofenadine is about 60 mg to about 180 mg.

5. The method of claim 3 wherein the composition is in the form of a tablet, lozenge or chewing gum.

6. The method of claim 2 wherein the NSAID is ibuprofen and the co-agent is ketotifen.

7. The method of claim 6 wherein the amount of ibuprofen is about 1200 mg to about 1600 mg, and the amount of ketotifen is about 0.5 mg to about 3 mg.

8. The method of claim 7 wherein a daily dose of about 2400 mg of ibuprofen and a daily dose of about 2 mg ketotifen are administered.

9. The method of claim 6 wherein the composition is in the form of a tablet, lozenge or chewing gum.

10. A method of inhibiting dependence to an opioid by a human subject in need thereof, comprising:

administering to the subject an effective amount of a pharmaceutical composition during an opioid therapy, wherein the pharmaceutical composition consists of active agents:

a) about 1200 mg to about 1600 mg of ibuprofen, and

b) about 0.5 mg to about 3 mg ketotifen,

wherein dependence to an opioid is inhibited in the human subject.

11. The method of claim 10 wherein a daily dose of about 2400 mg of ibuprofen and a daily dose of about 2 mg ketotifen are administered.

12. The method of claim 10 wherein the composition is in the form of a tablet, lozenge or chewing gum.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2024
From: IVERSEN, JACQUELINE M.; DAHL, THOMAS A.
To: SEN-JAM PHARMACEUTICAL LLC
Reel/Frame 068567/0515 →
MERGER Recorded Sep 12, 2024
From: SEN-JAM PHARMACEUTICAL LLC
To: SEN-JAM PHARMACEUTICAL INC.
Reel/Frame 068946/0721 →
Continuity (4)
Continuation 16896928 · Jun 9, 2020
Continuation 16133458 · Sep 17, 2018
Provisional Application 62560046 · Sep 18, 2017
Related Publication 20210212971A1 · Jul 15, 2021
References Cited (4)
WO WO2016140933A2 · 2016 [cited by examiner]
WO WO2016154028A1 · 2016 [cited by examiner]
Simons, et al. World Allergy Organ J. Sep. 2008; 1(9):145-155. [cited by examiner]
Ketotifen [online] retrieved from the internet on Mar. 6, 2024; (URL; https://go.drugbank.com/drugs/DB00920). [cited by examiner]